The BMC has provided input on the following: the development of new Guidelines in December 2023; the Draft Guidelines consultation in December 2022; the proposed Guideline revisions related to Gap medicines, comparator countries and international price tests in August 2021; the proposed Guideline Monitoring and Evaluation Plan in June 2021; the draft Guidelines in August and February 2020; the pro. [...] Discussion points: Supporting accessible engagement We challenge the PMPRB to understand, recognize and embrace the value and contribution that patients and the organizations that represent them can provide to the PMPRB as it develops and refines guiding principles, policies and processes. [...] We believe that the patient voice has a rightful place in informing the direction of the PMPRB about patent medicines and thus is incumbent on the PMPRB to ensure that patients and the organizations that represent them can effectively participate and contribute. [...] The BMC recognizes the measures that the PMPRB has taken recently to engage with the patient community, including the patient group round table held in early 2024, and the prospect of similar ongoing forums is welcomed. [...] Specifically, we seek answers to the following questions: how will patients share views and insights on an ongoing basis? How will the patient community be informed about decisions? What will be the ongoing point of contact for the patient community at the PMPRB? We urge the PMPRB to consider a progressive and meaningful approach to embedding a diverse range of voices in policy setting and directi.
- Pages
- 6
- Published in
- Canada
Table of Contents
- Input on the Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines 1
- September 11 2024 1
- Input on the Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines 2
- Introduction 2
- Core Positions on Drug Pricing Regulations 2
- Considerations regarding the Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines 3
- Discussion Guide 3
- Supporting accessible engagement. 3
- Impact assessment to enable evaluation. 3
- Inclusive approaches to pricing complaints. 3
- Certainty regarding availability and access. 3
- Discussion points Supporting accessible engagement 3
- Impact assessment to enable evaluation. 4
- Inclusive approaches to pricing complaints. 4
- Certainty regarding availability and access. Conclusion 5
- About the Best Medicines Coalition 6